Multicenter Phase II Study: Bendamustine plus Bortezomib plus Dexamethasone in the treatment of stage II/III relapsed or refractory multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2013
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 23 Mar 2012 Additional lead trial centre identified as reported by European Clinical Trials Database record.